CSPC Pharmaceutical Group Limited's latest marketcap:
As of 06/16/2025, CSPC Pharmaceutical Group Limited's market capitalization has reached $12.73 B. According to our data, CSPC Pharmaceutical Group Limited is the 1536th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 12.73 B |
| Revenue (ttm) | 3.69 B |
| Net Income (ttm) | 572.49 M |
| Shares Out | 11.43 B |
| EPS (ttm) | 0.05 |
| Forward PE | 17.64 |
| Ex-Dividend Date | 06/04/2025 |
| Earnings Date | 05/23/2025 |
CSPC Pharmaceutical Group Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/16/2025 | HK$12.73 B | 83.13% | 1536 |
| 12/31/2024 | HK$55.17 B | -35.87% | 2281 |
| 12/29/2023 | HK$86.02 B | -11.96% | 1481 |
| 12/30/2022 | HK$97.71 B | -3.19% | 1257 |
| 12/31/2021 | HK$100.93 B | 6.47% | 1467 |
| 12/31/2020 | HK$94.8 B | -18.19% | 1360 |
| 12/31/2019 | HK$115.87 B | 64.42% | 934 |
| 12/31/2018 | HK$70.47 B | -28.47% | 1234 |
| 12/29/2017 | HK$98.51 B | 96.58% | 1029 |
| 12/30/2016 | HK$50.11 B | 7.05% | 1533 |
Company Profile
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company specializing in the research, development, manufacture, and sale of pharmaceutical products. Headquartered in Shijiazhuang, China, the company operates globally, serving markets in Asia, North America, Europe, and beyond.
Business Segments
The company operates through three key segments:
- Finished Drugs – Produces a wide range of pharmaceutical products.
- Bulk Products – Supplies active pharmaceutical ingredients (APIs).
- Functional Food and Others – Includes healthcare and wellness products.
Key Products
- NBP Soft Capsules & Injections – For acute ischemic stroke.
- Oulaining Capsules & Injections – Treats memory and mental impairment.
- Enxi – For idiopathic Parkinson’s disease.
- Duomeisu – Targets lymphoma, multiple myeloma, and other cancers.
- Jinyouli – Prevents chemotherapy-induced leucopenia.
- Keaili – Used in breast cancer treatment.
- Shuluoke, Nuomoling, Weihong, Xinweihong – Antibiotics for infections.
- Xuanning – For hypertension management.
- Encun – Prevents atherosclerotic thrombosis.
- Gubang & Gubangjia – Treats osteoporosis in postmenopausal women.
- Gaoshunsong – Addresses arthritis, pain, and soft tissue injuries.
Additional Offerings
- Debixin – For ulcer treatment.
- Qimaite – Manages acute and chronic pain.
- APIs – Including antibiotics, vitamin C, and caffeine.
- Functional Food & Glucose Products – Supports wellness.
- Healthcare Services – Expands patient care solutions.
Strategic Partnerships
CSPC has a collaboration with Pfizer Inc. to distribute the COVID-19 oral therapeutic Nirmatrelvir/Ritonavir in China.
Company Background
Originally named China Pharmaceutical Group Limited, the company rebranded as CSPC Pharmaceutical Group Limited in March 2013. Founded in 1992, it has grown into a leading pharmaceutical player with a strong global presence.
Frequently Asked Questions
-
What is CSPC Pharmaceutical Group Limited's (HKG-1093) current market cap?As of 06/16/2025, CSPC Pharmaceutical Group Limited (including the parent company, if applicable) has an estimated market capitalization of $12.73 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does CSPC Pharmaceutical Group Limited (HKG-1093) rank globally by market cap?CSPC Pharmaceutical Group Limited global market capitalization ranking is approximately 1536 as of 06/16/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.